Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

3(42.9%)

7Total

Phase 1(4)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03719300Phase 2Terminated

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Role: lead

NCT01413087Phase 2Terminated

Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

Role: lead

NCT00826150Phase 1Completed

Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer

Role: lead

NCT00595088Phase 2Completed

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Role: lead

NCT00711997Phase 1Completed

Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer

Role: lead

NCT01878188Phase 1Completed

Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Role: lead

NCT00393809Phase 1Completed

Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer

Role: collaborator

All 7 trials loaded